Stephen Sofen

Stephen Sofen, Ph.D. Dr. Sofen brings over 20 years of varied biotech CMC experience from stints at Genzyme, Biogen, CRISPR Therapeutics, Kaleido Biosciences, and Abata Therapeutics as well as numerous consulting and advising roles primarily at venture firms and biotech start-ups. Projects span numerous platform technologies including small molecules, mono- and polyclonal antibodies, recombinant proteins, autologous and allogeneic gene edited cell therapies, viral vectors, and polymeric drugs.